Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Show more

Location: 700 Quince Orchard Road, Gaithersburg, MD, 20878, United States | Website: https://www.novavax.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.50B

52 Wk Range

$5.01 - $10.64

Previous Close

$9.23

Open

$9.25

Volume

4,479,117

Day Range

$9.23 - $9.60

Enterprise Value

988.1M

Cash

762.9M

Avg Qtr Burn

-94.58M

Insider Ownership

8.75%

Institutional Own.

62.36%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Update

Approved

Update

Approved

Update

Approved

Update

Phase 3

Update

Phase 3

Update

Phase 2

Update

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued


We track quarterly 13F filings for some of the largest biotech hedge funds here.